Evidence map›Paper›PMID 30883245›Full record

ArticleJournal of clinical oncology : official journal of the American Society of Clinical Oncology2019

Deleterious Germline Mutations Are a Risk Factor for Neoplastic Progression Among High-Risk Individuals Undergoing Pancreatic Surveillance.

Toshiya Abe, Amanda L Blackford, Koji Tamura, Madeline Ford, Patrick McCormick, Miguel Chuidian, Jose Alejandro Almario, Michael Borges, Anne Marie Lennon, Eun Ji Shin and 4 more

Registry-linked trialOpen access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06330441 (Pancreatic Cancer Screening in a Population at High Risk), which is not on this map. Cited by 49 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
49citing papers in PubMed, 2 pooled it
5.2field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06330441 narecruitingnot on this mapstarted 2022, after this paper: background citation

Pancreatic Cancer Screening in a Population at High Risk

TypeinterventionalSponsorMasaryk Memorial Cancer InstituteRan2022 to 2028Enrolled700ConditionsPancreatic Ductal Adenocarcinoma, Hereditary Diseases, Pancreatitis, ChronicArmsendoscopic ultrasonography, magnetic resonance, laboratory examination
3 · Its place in the literature

Who cites it

49 citing papers in PubMed, 2 syntheses or guidelines pooled it, 105 citations in OpenAlex.

  1. Guideline
  2. Pooled it
  3. Trial
  4. Alterations in the Duodenal Fluid Microbiome of Patients With Pancreatic Cancer.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2022
    Trial
  5. Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Review
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 1 institution in 1 country.

Toshiya Abe1 Johns Hopkins Medical Institutions, Baltimore, MD.
Amanda L Blackford1 Johns Hopkins Medical Institutions, Baltimore, MD.
Koji Tamura1 Johns Hopkins Medical Institutions, Baltimore, MD.
Madeline Ford1 Johns Hopkins Medical Institutions, Baltimore, MD.
Patrick McCormick1 Johns Hopkins Medical Institutions, Baltimore, MD.
Miguel Chuidian1 Johns Hopkins Medical Institutions, Baltimore, MD.
Jose Alejandro Almario1 Johns Hopkins Medical Institutions, Baltimore, MD.
Michael Borges1 Johns Hopkins Medical Institutions, Baltimore, MD.
Anne Marie Lennon1 Johns Hopkins Medical Institutions, Baltimore, MD.
Eun Ji Shin1 Johns Hopkins Medical Institutions, Baltimore, MD.
Alison P Klein1 Johns Hopkins Medical Institutions, Baltimore, MD.
Ralph H Hruban1 Johns Hopkins Medical Institutions, Baltimore, MD.
Marcia I Canto1 Johns Hopkins Medical Institutions, Baltimore, MD.
Michael Goggins1 Johns Hopkins Medical Institutions, Baltimore, MD.
Johns Hopkins University · US

Funding

Tumor Antigens for Individual Signatures and TherapyP50CA062924 · NCI · JOHNS HOPKINS UNIVERSITY · PI LENNON, ANNE MARIE · 1993 to 2022
$54.6M
Using Markers to Improve Pancreatic Cancer ScreeningR01CA176828 · NCI · JOHNS HOPKINS UNIVERSITY · PI GOGGINS, MICHAEL G. · 2013 to 2024
$4.1M
NCI NIH HHS P50 CA062924NCI NIH HHS R01 CA176828
6 · The paper itself

Abstract

purposeTo compare the risk of neoplastic progression by germline mutation status versus family history without a known germline mutation (familial risk) among individuals with an increased risk for pancreatic cancer who are undergoing surveillance.

methodsOf 464 high-risk individuals in the Cancer of the Pancreas Screening program at Johns Hopkins Hospital who were undergoing pancreatic surveillance, 119 had a known deleterious germline mutation in a pancreatic cancer susceptibility gene; 345 met family history criteria for pancreatic surveillance but were not known to harbor a germline mutation. We used next-generation sequencing to identify previously unrecognized germline mutations among these 345 individuals. We compared the development of pancreatic cancer, high-grade dysplasia, or clinically worrisome features, adjusting for competing mortality, among all germline mutation carriers with the risk of progression in a cohort without a known germline mutation.

resultsFifteen (4.3%) of 345 individuals classified as having familial risk had a previously unrecognized pancreatic cancer susceptibility gene mutation (nine that involved

conclusionThe cumulative incidence of pancreatic cancer is significantly higher among individuals with an identifiable deleterious germline mutation in a pancreatic cancer susceptibility gene than it is among individuals with a strong family history but no identified mutation. Gene testing of individuals who meet criteria for pancreatic surveillance on the basis of their family history may better define those most at risk for neoplastic progression.

Indexed as

Germ-Line MutationAgedAtaxia Telangiectasia Mutated ProteinsBRCA1 ProteinBRCA2 ProteinCarcinoma, Pancreatic DuctalDisease ProgressionEarly Detection of CancerFanconi Anemia Complementation Group N ProteinFemaleGenetic Predisposition to DiseaseHumansMaleMedical History TakingMiddle AgedPancreatic NeoplasmsAtaxia Telangiectasia Mutated ProteinsATM protein, humanBRCA1 ProteinBRCA1 protein, humanBRCA2 ProteinBRCA2 protein, humanFanconi Anemia Complementation Group N ProteinPALB2 protein, humanTP53 protein, humanTumor Suppressor Protein p53

Identifiers

PMID30883245
PMCPMC6494358
OpenAlexW2920864397

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.